Intellectual property rights, especially patents, frequently form the foundation of value in a life sciences company. If conducted with eventual commercial success in mind, a due diligence review of an IP portfolio can enable an investor to assess more accurately the present and future value of the technology and IP associated with an investment. Often times however, little thought is given as to how to leverage the harvested intelligence in the commercialization process of the acquired technology after the deal. This panel discussed:
- The IP due diligence process – what to expect and preparing for the unexpected
- Working the IP – identifying and valuing know-how to execute the IP
- The technology factor – working with R & D during and after the diligence process
Related Insights
December 19, 2025
Health Care Law Today
Gender Affirming Care for Minors: CMS and HHS Propose Limits on “Sex Rejection Procedures” and Expanded Enforcement Pathways
On December 18, 2025, the U.S. Department of Health and Human Services (HHS) held a press conference focused on what is defined as “sex…
December 19, 2025
Foley Viewpoints
Prohibition to Prescription: What Trump’s Marijuana Executive Order Really Means
On December 18, 2025, President Donald Trump issued an Executive Order, Increasing Medical Marijuana and Cannabidiol Research, that…
December 18, 2025
Manufacturing Industry Advisor
Foley Automotive Update
Analysis by Julie Dautermann, Competitive Intelligence Analyst Foley is here to help you through all aspects of rethinking your long-term…